Literature DB >> 21898123

The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction.

Ziv Gan-Or1, Anat Bar-Shira, Anat Mirelman, Tanya Gurevich, Nir Giladi, Avi Orr-Urtreger.   

Abstract

The current paradigm on Parkinson's disease (PD) pathogenesis and course suggests the involvement of multiple genes and the interaction between them. Recently, it was reported that a variation (rs2435207) in the MAPT gene region influenced the age of motor symptoms onset (AO) in 44 PD patients from 19 families, carriers of leucine-rich repeat kinase 2 (LRRK2) mutations, all of European and North American origin. To examine whether genetic factors within the MAPT locus exert a similar effect on AO in a different population of LRRK2-associated PD patients, 99 unrelated Ashkenazi patients with the LRRK2 p.G2019S mutation were analyzed. Three SNPs in the MAPT region were studied, rs393152, rs2435207, and rs11079727; the latter is located in the first intron of MAPT. Among carriers of the single LRRK2 p.G2019S mutation that did not carry a founder Ashkenazi GBA mutation too (n = 84), the AO in minor rs11079727 A allele carriers (C/A genotype) was significantly older (62.5 ± 10.6 years) compared to the AO (55.7 ± 11.6) among carriers of the C/C genotype (p = 0.025). Our results further support a possible interaction between genetic factors in the MAPT region and the LRRK2 gene, which influence the clinical course of PD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21898123     DOI: 10.1007/s12031-011-9641-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  15 in total

1.  Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2011-08-12       Impact factor: 2.660

2.  Genetic factors influencing age at onset in LRRK2-linked Parkinson disease.

Authors:  Yulia Golub; Daniela Berg; Donald B Calne; Ronald F Pfeiffer; Ryan J Uitti; A Jon Stoessl; Zbigniew K Wszolek; Matthew J Farrer; Jakob C Mueller; Thomas Gasser; Julia Fuchs
Journal:  Parkinsonism Relat Disord       Date:  2008-11-28       Impact factor: 4.891

3.  Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?

Authors:  Joanna M Biernacka; Sebastian M Armasu; Julie M Cunningham; J Eric Ahlskog; Sun Ju Chung; Demetrius M Maraganore
Journal:  Parkinsonism Relat Disord       Date:  2011-08-03       Impact factor: 4.891

4.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology.

Authors:  A Rajput; D W Dickson; C A Robinson; O A Ross; J C Dächsel; S J Lincoln; S A Cobb; M L Rajput; M J Farrer
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

5.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Authors:  H L Melrose; J C Dächsel; B Behrouz; S J Lincoln; M Yue; K M Hinkle; C B Kent; E Korvatska; J P Taylor; L Witten; Y-Q Liang; J E Beevers; M Boules; B N Dugger; V A Serna; A Gaukhman; X Yu; M Castanedes-Casey; A T Braithwaite; S Ogholikhan; N Yu; D Bass; G Tyndall; G D Schellenberg; D W Dickson; C Janus; M J Farrer
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 7.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

8.  Linkage disequilibrium and association of MAPT H1 in Parkinson disease.

Authors:  Lisa Skipper; Kristen Wilkes; Mathias Toft; Matthew Baker; Sarah Lincoln; Mary Hulihan; Owen A Ross; Mike Hutton; Jan Aasly; Matthew Farrer
Journal:  Am J Hum Genet       Date:  2004-08-03       Impact factor: 11.025

9.  LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.

Authors:  Z Gan-Or; A Bar-Shira; A Mirelman; T Gurevich; M Kedmi; N Giladi; A Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-05-21       Impact factor: 2.660

10.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  13 in total

1.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

2.  Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant.

Authors:  Rachel Saunders-Pullman; Roberto Angel Ortega; Cuiling Wang; Deborah Raymond; Sonya Elango; Katherine Leaver; Nikita Urval; Viktoriya Katsnelson; Rachel Gerber; Matthew Swan; Vicki Shanker; Roy N Alcalay; Anat Mirelman; Michael C Brumm; Helen Mejia-Santana; Christopher S Coffey; Kenneth Marek; Laurie J Ozelius; Nir Giladi; Karen S Marder; Susan B Bressman
Journal:  Neurology       Date:  2022-06-03       Impact factor: 11.800

Review 3.  Tau and MAPT genetics in tauopathies and synucleinopathies.

Authors:  Etienne Leveille; Owen A Ross; Ziv Gan-Or
Journal:  Parkinsonism Relat Disord       Date:  2021-09-14       Impact factor: 4.402

4.  Age of onset: can we rely on essential tremor patients to report this? Data from a prospective, longitudinal study.

Authors:  Elan D Louis
Journal:  Neuroepidemiology       Date:  2012-10-24       Impact factor: 3.282

5.  The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease.

Authors:  Z Gan-Or; I Amshalom; A Bar-Shira; M Gana-Weisz; A Mirelman; K Marder; S Bressman; N Giladi; A Orr-Urtreger
Journal:  J Neurol       Date:  2015-08-02       Impact factor: 4.849

6.  No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease.

Authors:  Victoria Berge-Seidl; Lasse Pihlstrøm; Zbigniew K Wszolek; Owen A Ross; Mathias Toft
Journal:  Neurobiol Aging       Date:  2018-09-22       Impact factor: 4.673

7.  Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression.

Authors:  Albert A Davis; Kristin M Andruska; Bruno A Benitez; Brad A Racette; Joel S Perlmutter; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2015-09-30       Impact factor: 4.673

Review 8.  LRRK2: cause, risk, and mechanism.

Authors:  Coro Paisán-Ruiz; Patrick A Lewis; Andrew B Singleton
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

Review 9.  The pallidopyramidal syndromes: nosology, aetiology and pathogenesis.

Authors:  Eleanna Kara; John Hardy; Henry Houlden
Journal:  Curr Opin Neurol       Date:  2013-08       Impact factor: 5.710

Review 10.  TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Authors:  Helen Ling; Eleanna Kara; Rina Bandopadhyay; John Hardy; Janice Holton; Georgia Xiromerisiou; Andrew Lees; Henry Houlden; Tamas Revesz
Journal:  Neurobiol Aging       Date:  2013-05-09       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.